We have applied our expertise in multivalency to discover product candidates and lead compounds in a number of therapeutic areas.

We believe that our lead product candidates have demonstrated in relevant preclinical models, potential advantages such as substantial increases in potency, duration of action and/or selectivity relative to existing medicines or potential medicines in late-stage clinical studies.

The table below summarizes the status of our approved product and our most advanced product candidates for internal development or co-development. The table also includes the status of respiratory programs in which we have an economic interest that are being developed and commercialized by GSK pursuant to agreements with Theravance, Inc., which we refer to as the GSK-partnered respiratory programs.

THERAPEUTIC AREA STATUS
Program Phase 1 Phase 2 Phase 3 Filed
ECONOMIC INTERESTS IN GSK RESPIRATORY PROGRAMS
UMEC/VI/FF
GSK961081 (MABA)
 
THERAVANCE BIOPHARMA DEVELOPMENT PROGRAMS
 
Bacterial Infections
TD-1792
TD-1607
 
CNS/Pain
Axelopran (TD-1211): Opioid - Induced Constipation
TD-9855: Fibromyalgia
 
Respiratory
TD-4208 (LAMA)
 
GI Motility Dysfunction
Velusetrag (TD-5108)
TD-8954
Theravance Printable Pipeline

Key:

  • CNS: Central Nervous System
  • FF: Fluticasone Furoate 
  • GI: Gastrointestinal
  • LAMA: Long-Acting Muscarinic Antagonist
  • MABA: Bifunctional Muscarinic Antagonist-Beta2 Agonist
  • UMEC: Umeclidinium
  • VI: Vilanterol

In the table above:

  • Status indicates the most advanced stage of clinical development that has been completed or is in process.
  • Phase 1 indicates initial clinical safety testing in healthy volunteers, or studies directed toward understanding the mechanisms of action of the drug.
  • Phase 2 indicates further clinical safety testing and preliminary efficacy testing in a limited patient population.
  • Phase 3 indicates evaluation of clinical efficacy and safety within an expanded patient population.
  • Filed indicates that a marketing application has been submitted to a regulatory authority. 
Form content here please :)